Cargando…

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer

OBJECTIVE: We evaluated whether the blood parameters before prostate biopsy can diagnose prostate cancer (PCa) and clinically significant PCa (Gleason score [GS] ≥7) in our hospital. METHODS: This study included patients with increased prostate-specific antigen (PSA) up to 20 ng/mL. The associations...

Descripción completa

Detalles Bibliográficos
Autores principales: Nepal, Sat Prasad, Nakasato, Takehiko, Fukagai, Takashi, Ogawa, Yoshio, Nakagami, Yoshihiro, Shichijo, Takeshi, Morita, Jun, Maeda, Yoshiko, Oshinomi, Kazuhiko, Unoki, Tsutomu, Noguchi, Tetsuo, Inoue, Tatsuki, Kato, Ryosuke, Amano, Satoshi, Mizunuma, Moyuru, Kurokawa, Masahiro, Tsunokawa, Yoshiki, Yasuda, Sou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023529/
https://www.ncbi.nlm.nih.gov/pubmed/36942115
http://dx.doi.org/10.1016/j.ajur.2022.02.007
_version_ 1784908902622560256
author Nepal, Sat Prasad
Nakasato, Takehiko
Fukagai, Takashi
Ogawa, Yoshio
Nakagami, Yoshihiro
Shichijo, Takeshi
Morita, Jun
Maeda, Yoshiko
Oshinomi, Kazuhiko
Unoki, Tsutomu
Noguchi, Tetsuo
Inoue, Tatsuki
Kato, Ryosuke
Amano, Satoshi
Mizunuma, Moyuru
Kurokawa, Masahiro
Tsunokawa, Yoshiki
Yasuda, Sou
author_facet Nepal, Sat Prasad
Nakasato, Takehiko
Fukagai, Takashi
Ogawa, Yoshio
Nakagami, Yoshihiro
Shichijo, Takeshi
Morita, Jun
Maeda, Yoshiko
Oshinomi, Kazuhiko
Unoki, Tsutomu
Noguchi, Tetsuo
Inoue, Tatsuki
Kato, Ryosuke
Amano, Satoshi
Mizunuma, Moyuru
Kurokawa, Masahiro
Tsunokawa, Yoshiki
Yasuda, Sou
author_sort Nepal, Sat Prasad
collection PubMed
description OBJECTIVE: We evaluated whether the blood parameters before prostate biopsy can diagnose prostate cancer (PCa) and clinically significant PCa (Gleason score [GS] ≥7) in our hospital. METHODS: This study included patients with increased prostate-specific antigen (PSA) up to 20 ng/mL. The associations of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) alone or with PSA with PCa and clinically significant PCa were analyzed. RESULTS: We included 365 patients, of whom 52.9% (193) had PCa including 66.8% (129) with GS of ≥7. PSA density (PSAD) and PSA had better the area under the curve (AUC) of 0.722 and 0.585, respectively with p=0.001 for detecting PCa compared with other blood parameters. PSA combined with PLR (PsPLR) and PSA with NLR (PsNLR) had better AUC of 0.608 and 0.610, respectively with p<0.05, for diagnosing GS≥7 population, compared with PSA, free/total PSA, NLR, PLR, and PsNPLR (PSA combined with NLR and PLR). NLR and PLR did not predict PCa on multivariate analysis. For GS≥7 cancer detection, in the multivariate analysis, separate models with PSA and NLR (Model 1: PsNLR+baseline parameters) or PSA and PLR (Moder 2: PsPLR+baseline parameters) were made. Baseline parameters comprised age, digital rectal exam-positive lesions, PSA density, free/total PSA, and magnetic resonance imaging. Model 2 containing PsPLR was statistically significant (odds ratio: 2.862, 95% confidence interval: 1.174–6.975, p=0.021) in finding aggressive PCa. The predictive accuracy of Model 2 was increased (AUC: 0.734, p<0.001) than that when only baseline parameters were used (AUC: 0.693, p<0.001). CONCLUSION: NLR or PLR, either alone or combined with PSA, did not detect PCa. However, the combined use of PSA with PLR could find the differences between clinically significant and insignificant PCa in our retrospective study limited by the small number of samples.
format Online
Article
Text
id pubmed-10023529
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Second Military Medical University
record_format MEDLINE/PubMed
spelling pubmed-100235292023-03-19 Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer Nepal, Sat Prasad Nakasato, Takehiko Fukagai, Takashi Ogawa, Yoshio Nakagami, Yoshihiro Shichijo, Takeshi Morita, Jun Maeda, Yoshiko Oshinomi, Kazuhiko Unoki, Tsutomu Noguchi, Tetsuo Inoue, Tatsuki Kato, Ryosuke Amano, Satoshi Mizunuma, Moyuru Kurokawa, Masahiro Tsunokawa, Yoshiki Yasuda, Sou Asian J Urol Original Article OBJECTIVE: We evaluated whether the blood parameters before prostate biopsy can diagnose prostate cancer (PCa) and clinically significant PCa (Gleason score [GS] ≥7) in our hospital. METHODS: This study included patients with increased prostate-specific antigen (PSA) up to 20 ng/mL. The associations of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) alone or with PSA with PCa and clinically significant PCa were analyzed. RESULTS: We included 365 patients, of whom 52.9% (193) had PCa including 66.8% (129) with GS of ≥7. PSA density (PSAD) and PSA had better the area under the curve (AUC) of 0.722 and 0.585, respectively with p=0.001 for detecting PCa compared with other blood parameters. PSA combined with PLR (PsPLR) and PSA with NLR (PsNLR) had better AUC of 0.608 and 0.610, respectively with p<0.05, for diagnosing GS≥7 population, compared with PSA, free/total PSA, NLR, PLR, and PsNPLR (PSA combined with NLR and PLR). NLR and PLR did not predict PCa on multivariate analysis. For GS≥7 cancer detection, in the multivariate analysis, separate models with PSA and NLR (Model 1: PsNLR+baseline parameters) or PSA and PLR (Moder 2: PsPLR+baseline parameters) were made. Baseline parameters comprised age, digital rectal exam-positive lesions, PSA density, free/total PSA, and magnetic resonance imaging. Model 2 containing PsPLR was statistically significant (odds ratio: 2.862, 95% confidence interval: 1.174–6.975, p=0.021) in finding aggressive PCa. The predictive accuracy of Model 2 was increased (AUC: 0.734, p<0.001) than that when only baseline parameters were used (AUC: 0.693, p<0.001). CONCLUSION: NLR or PLR, either alone or combined with PSA, did not detect PCa. However, the combined use of PSA with PLR could find the differences between clinically significant and insignificant PCa in our retrospective study limited by the small number of samples. Second Military Medical University 2023-04 2022-03-05 /pmc/articles/PMC10023529/ /pubmed/36942115 http://dx.doi.org/10.1016/j.ajur.2022.02.007 Text en © 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Nepal, Sat Prasad
Nakasato, Takehiko
Fukagai, Takashi
Ogawa, Yoshio
Nakagami, Yoshihiro
Shichijo, Takeshi
Morita, Jun
Maeda, Yoshiko
Oshinomi, Kazuhiko
Unoki, Tsutomu
Noguchi, Tetsuo
Inoue, Tatsuki
Kato, Ryosuke
Amano, Satoshi
Mizunuma, Moyuru
Kurokawa, Masahiro
Tsunokawa, Yoshiki
Yasuda, Sou
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
title Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
title_full Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
title_fullStr Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
title_full_unstemmed Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
title_short Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
title_sort neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023529/
https://www.ncbi.nlm.nih.gov/pubmed/36942115
http://dx.doi.org/10.1016/j.ajur.2022.02.007
work_keys_str_mv AT nepalsatprasad neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT nakasatotakehiko neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT fukagaitakashi neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT ogawayoshio neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT nakagamiyoshihiro neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT shichijotakeshi neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT moritajun neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT maedayoshiko neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT oshinomikazuhiko neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT unokitsutomu neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT noguchitetsuo neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT inouetatsuki neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT katoryosuke neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT amanosatoshi neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT mizunumamoyuru neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT kurokawamasahiro neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT tsunokawayoshiki neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer
AT yasudasou neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer